Thus, our findings indicate that SGK1 inhibition is a broadly applicable therapy regardless of the stage of neurodegenerative disorders (brain injuries) or the polarity of the glia because it can not only potentiate the neurotrophic functions of glia at the early disease stage, but also alleviate or correct the neurotoxic properties of glia in chronic disease environments. Here, SGK1 is linked to brain injury.